RxSight, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M | $14.7M |
| Cost of Revenue | — | $31.5M | $41.0M | $35.3M | $27.7M | $18.1M | $13.0M |
| Gross Profit | — | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M | $1.7M |
| Gross Margin | — | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% | 11.6% |
| Operating Expenses | |||||||
| Research & Development | — | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M | $21.9M |
| SG&A Expense | — | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M | $15.2M |
| Operating Income | — | $-48.2M | $-36.9M | $-50.1M | $-63.3M | $-52.8M | $-35.4M |
| Operating Margin | — | -35.8% | -26.3% | -56.2% | -129.2% | -233.6% | -241.3% |
| Interest Expense | — | $19.0K | $21.0K | $3.3M | $4.9M | $3.7M | $510.0K |
| Pretax Income | — | $-38.9M | $-27.4M | $-48.6M | $-66.7M | $-48.7M | $27.6M |
| Income Tax Expense | — | $66.0K | $50.0K | $20.0K | $9.0K | $8.0K | $57.0K |
| Net Income | — | $-38.9M | $-27.5M | $-48.6M | $-66.8M | $-48.7M | $27.6M |
| Net Margin | — | -29.0% | -19.6% | -54.6% | -136.2% | -215.5% | 187.9% |
| EPS (Basic) | — | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-1.79 | $0.23 |
| EPS (Diluted) | — | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-1.79 | $0.04 |
| Shares Outstanding (Basic) | 41.3M | 40.9M | 38.9M | 34.5M | 27.7M | 27.3M | 14.8M |
| Shares Outstanding (Diluted) | 41.3M | 40.9M | 38.9M | 34.5M | 27.7M | 27.3M | 22.1M |
| Dividends Per Share | — | — | — | — | — | — | — |